These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3028 related items for PubMed ID: 19001320

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L.
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [Abstract] [Full Text] [Related]

  • 6. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
    Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C.
    Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
    [Abstract] [Full Text] [Related]

  • 7. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
    Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, de Braud F, Barni S.
    Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
    [Abstract] [Full Text] [Related]

  • 8. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
    Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A.
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
    [Abstract] [Full Text] [Related]

  • 9. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
    Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG.
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID.
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [Abstract] [Full Text] [Related]

  • 12. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):674-88. PubMed ID: 21398618
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
    Genet Med; 2013 Jul 20; 15(7):517-27. PubMed ID: 23429431
    [Abstract] [Full Text] [Related]

  • 15. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
    Lin JK, Lin AJ, Lin CC, Lan YT, Yang SH, Li AF, Chang SC.
    J Surg Oncol; 2011 Nov 01; 104(6):661-6. PubMed ID: 21671463
    [Abstract] [Full Text] [Related]

  • 16. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F.
    J Clin Oncol; 2011 May 20; 29(15):2011-9. PubMed ID: 21502544
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
    De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S.
    Lancet Oncol; 2010 Aug 20; 11(8):753-62. PubMed ID: 20619739
    [Abstract] [Full Text] [Related]

  • 20. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
    Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, Mori T, Komine K, Iwama N, Kato S, Ishioka C.
    Int J Clin Oncol; 2013 Aug 20; 18(4):670-7. PubMed ID: 22638623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 152.